Artificial Intelligence-Enabled ECG Algorithm to Identify Patients With Left Ventricular Systolic Dysfunction Presenting to the Emergency Department With Dyspnea.


Journal

Circulation. Arrhythmia and electrophysiology
ISSN: 1941-3084
Titre abrégé: Circ Arrhythm Electrophysiol
Pays: United States
ID NLM: 101474365

Informations de publication

Date de publication:
08 2020
Historique:
entrez: 28 9 2020
pubmed: 29 9 2020
medline: 11 11 2020
Statut: ppublish

Résumé

Identification of systolic heart failure among patients presenting to the emergency department (ED) with acute dyspnea is challenging. The reasons for dyspnea are often multifactorial. A focused physical evaluation and diagnostic testing can lack sensitivity and specificity. The objective of this study was to assess the accuracy of an artificial intelligence-enabled ECG to identify patients presenting with dyspnea who have left ventricular systolic dysfunction (LVSD). We retrospectively applied a validated artificial intelligence-enabled ECG algorithm for the identification of LVSD (defined as LV ejection fraction ≤35%) to a cohort of patients aged ≥18 years who were evaluated in the ED at a Mayo Clinic site with dyspnea. Patients were included if they had at least one standard 12-lead ECG acquired on the date of the ED visit and an echocardiogram performed within 30 days of presentation. Patients with prior LVSD were excluded. We assessed the model performance using area under the receiver operating characteristic curve, accuracy, sensitivity, and specificity. A total of 1606 patients were included. Median time from ECG to echocardiogram was 1 day (Q1: 1, Q3: 2). The artificial intelligence-enabled ECG algorithm identified LVSD with an area under the receiver operating characteristic curve of 0.89 (95% CI, 0.86-0.91) and accuracy of 85.9%. Sensitivity, specificity, negative predictive value, and positive predictive value were 74%, 87%, 97%, and 40%, respectively. To identify an ejection fraction <50%, the area under the receiver operating characteristic curve, accuracy, sensitivity, and specificity were 0.85 (95% CI, 0.83-0.88), 86%, 63%, and 91%, respectively. NT-proBNP (N-terminal pro-B-type natriuretic peptide) alone at a cutoff of >800 identified LVSD with an area under the receiver operating characteristic curve of 0.80 (95% CI, 0.76-0.84). The ECG is an inexpensive, ubiquitous, painless test which can be quickly obtained in the ED. It effectively identifies LVSD in selected patients presenting to the ED with dyspnea when analyzed with artificial intelligence and outperforms NT-proBNP. Graphic Abstract: A graphic abstract is available for this article.

Sections du résumé

BACKGROUND
Identification of systolic heart failure among patients presenting to the emergency department (ED) with acute dyspnea is challenging. The reasons for dyspnea are often multifactorial. A focused physical evaluation and diagnostic testing can lack sensitivity and specificity. The objective of this study was to assess the accuracy of an artificial intelligence-enabled ECG to identify patients presenting with dyspnea who have left ventricular systolic dysfunction (LVSD).
METHODS
We retrospectively applied a validated artificial intelligence-enabled ECG algorithm for the identification of LVSD (defined as LV ejection fraction ≤35%) to a cohort of patients aged ≥18 years who were evaluated in the ED at a Mayo Clinic site with dyspnea. Patients were included if they had at least one standard 12-lead ECG acquired on the date of the ED visit and an echocardiogram performed within 30 days of presentation. Patients with prior LVSD were excluded. We assessed the model performance using area under the receiver operating characteristic curve, accuracy, sensitivity, and specificity.
RESULTS
A total of 1606 patients were included. Median time from ECG to echocardiogram was 1 day (Q1: 1, Q3: 2). The artificial intelligence-enabled ECG algorithm identified LVSD with an area under the receiver operating characteristic curve of 0.89 (95% CI, 0.86-0.91) and accuracy of 85.9%. Sensitivity, specificity, negative predictive value, and positive predictive value were 74%, 87%, 97%, and 40%, respectively. To identify an ejection fraction <50%, the area under the receiver operating characteristic curve, accuracy, sensitivity, and specificity were 0.85 (95% CI, 0.83-0.88), 86%, 63%, and 91%, respectively. NT-proBNP (N-terminal pro-B-type natriuretic peptide) alone at a cutoff of >800 identified LVSD with an area under the receiver operating characteristic curve of 0.80 (95% CI, 0.76-0.84).
CONCLUSIONS
The ECG is an inexpensive, ubiquitous, painless test which can be quickly obtained in the ED. It effectively identifies LVSD in selected patients presenting to the ED with dyspnea when analyzed with artificial intelligence and outperforms NT-proBNP. Graphic Abstract: A graphic abstract is available for this article.

Identifiants

pubmed: 32986471
doi: 10.1161/CIRCEP.120.008437
doi:

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e008437

Commentaires et corrections

Type : CommentIn

Auteurs

Demilade Adedinsewo (D)

Division of Cardiovascular Medicine (D.A.), Mayo Clinic, Jacksonville, FL.

Rickey E Carter (RE)

Department of Health Sciences Research (R.E.C., P.J.), Mayo Clinic, Jacksonville, FL.

Zachi Attia (Z)

Division of Cardiovascular Medicine (Z.A., J.L.D., P.A.F., F.L.-J., P.A.N.), Mayo Clinic, Rochester, MN.

Patrick Johnson (P)

Department of Health Sciences Research (R.E.C., P.J.), Mayo Clinic, Jacksonville, FL.

Anthony H Kashou (AH)

Department of Medicine (A.H.K.), Mayo Clinic, Rochester, MN.

Jennifer L Dugan (JL)

Division of Cardiovascular Medicine (Z.A., J.L.D., P.A.F., F.L.-J., P.A.N.), Mayo Clinic, Rochester, MN.

Michael Albus (M)

Department of Emergency Medicine (M.A., J.M.S.), Mayo Clinic, Jacksonville, FL.

Johnathan M Sheele (JM)

Department of Emergency Medicine (M.A., J.M.S.), Mayo Clinic, Jacksonville, FL.

Fernanda Bellolio (F)

Department of Emergency Medicine (F.B.), Mayo Clinic, Rochester, MN.

Paul A Friedman (PA)

Division of Cardiovascular Medicine (Z.A., J.L.D., P.A.F., F.L.-J., P.A.N.), Mayo Clinic, Rochester, MN.

Francisco Lopez-Jimenez (F)

Division of Cardiovascular Medicine (Z.A., J.L.D., P.A.F., F.L.-J., P.A.N.), Mayo Clinic, Rochester, MN.

Peter A Noseworthy (PA)

Division of Cardiovascular Medicine (Z.A., J.L.D., P.A.F., F.L.-J., P.A.N.), Mayo Clinic, Rochester, MN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH